Compare FCNCP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCNCP | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.4B |
| IPO Year | 1995 | 1996 |
| Metric | FCNCP | VCEL |
|---|---|---|
| Price | $18.85 | $39.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 12.8K | ★ 439.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 97.95 | N/A |
| Revenue | ★ $9,541,000,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $18.84 | $28.95 |
| 52 Week High | $22.60 | $49.32 |
| Indicator | FCNCP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 25.38 | 44.28 |
| Support Level | N/A | $35.32 |
| Resistance Level | $20.64 | $41.12 |
| Average True Range (ATR) | 0.30 | 1.20 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 0.93 | 65.91 |
First Citizens is a US regional bank with total assets of around $237 billion as of June 30, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.